146 research outputs found

    Obraz Wiednia w krakowskim czasopiśmie "Życie" (1897 - 1899)

    Get PDF
    Der Hauptzweck dieser Arbeit war es, das Image von Wien und den Wienern in der Krakauer Zeitschrift ,,Życie“ (1897 – 1899) herausgegeben von Ludwik Szczepanski, Ignacy Sewera-Maciejowski und - vor allem - von Stanislaw Przybyszewski, darzustellen und zu analysieren. Das sekundäre Ziel ist das Bild der österreichischen Hauptstadt im Gegensatz zu Lemberg und vor allem mit Krakau zu vergleichen und die gegenseitigen Einflüsse im Kulturellen, Sozialen und Politischen zu untersuchen. Die Arbeit beginnt mit theoretischen Grundlagen, die einer Beschreibung des späten neunzehnten Jahrhunderts in Europa und ihre politischen, sozialen Bedingungen sowie des künstlerischen Lebens angehören. Weiter wird auch auf polnische Zeitschriften der Periode eingegangen, wobei der Schwerpunkt in erster Linie nach den Themen dieser Studie über die Entstehung, Eigenschaften und Programm von Krakaus ,,Życie“ liegt. Mit Artikeln, Essays oder Berichten von diesen drei Städten: Wien, Lemberg und Krakau wird das Wesen eines jeden dieser Orte beschrieben. Jedes Kapitel steht für eine Stadt, welches aus mehreren Abschnitten besteht. In der Analyse des städtischen Lebens wird auch auf das besetzten Polen eingegangen. Der Kern dieser Arbeit ist die Interpretation von Informationen durch das Lesen der Seriennummern der Zeitschrift ,,Życie“ (R.1, Nr. 1-14, R.2, Nr. 1-50, R.3, Nr. 1-21). Die aus dieser Arbeit resultierenden bzw. gesammelten Informationen und Daten aus der Analyse der Literatur, wurden mit einem interessanten und eindrucksvollen, aber vor allem ehrlichen Wien-Bild aus einer Perspektive von Redakteuren und Korrespondenten von „Życie“ dargestellt. Hier befinden sich auch einige Illustrationen aus dieser imposanten Kunstzeitschrift

    Exploring new horizons : unleashing tourism potential through innovative product development inspired by surfing : an introductory exploration

    Get PDF
    PURPOSE: The aim of this article is to present the physical, geographical and spatial conditions of surfing in the world, and in particular to indicate the possibilities of creating new tourist products for active tourists.DESIGN/METHODOLOGY/APPROACH: The modern market of tourist services needs new tourist products and new activities that allow us to create a new offer for tourists. The research hypothesis was defined as follows: The tourism industry and its infrastructure needs necessary to ensure efficient tourist service mean that the creation of new tourist products contributes to the development of a given space, and one of the development tools may be surfing.FINDINGS: Without a properly developed infrastructure for tourism, it is impossible to talk about its attractiveness and full operational and development functionality of the market. Tourism development based on specific tourist activities is a basic element of spatial development.PRACTICAL IMPLICATIONS: Surfing brings many benefits and opportunities, among which there is certainly the joy of contact with the element that is the ocean, or perhaps an element that cannot be mastered, but can be understood and, in harmony with its nature, managed for the benefit of many.ORIGINALITY/VALUE: The article has a practical application. The results can be used by people planning the development of traditional spatial tourism product.peer-reviewe

    Tests of 3 linear collider beam dynamics simulation programs

    Get PDF
    We report on tests of 3 linear collider beam dynamics simulation programs: PLACET, MERLIN, and LIAR. The programs are used to simulate the performance of the TESLA, NLC, and CLIC beamlines from the main linac to the IP. In each case the beamlines have no errors or misalignments

    TDR Technique for Estimating the Intensity of Evapotranspiration of Turfgrasses

    Get PDF
    The paper presents a method for precise estimation of evapotranspiration of selected turfgrass species. The evapotranspiration functions, whose domains are only two relatively easy to measure parameters, were developed separately for each of the grass species. Those parameters are the temperature and the volumetric moisture of soil at the depth of 2.5 cm. Evapotranspiration has the character of a modified logistic function with empirical parameters. It assumes the form ETRθ2.5 cm,T2.5 cm=A/1+B·e-C·θ2.5 cm·T2.5 cm, where: ETRθ2.5 cm,T2.5 cm is evapotranspiration [mm·h−1], θ2.5 cm is volumetric moisture of soil at the depth of 2.5 cm [m3·m−3], T2.5 cm is soil temperature at the depth of 2.5 cm [°C], and A, B, and C are empirical coefficients calculated individually for each of the grass species [mm·h1], and [—], [(m3·m−3·°C)−1]. The values of evapotranspiration calculated on the basis of the presented function can be used as input data for the design of systems for the automatic control of irrigation systems ensuring optimum moisture conditions in the active layer of lawn swards

    Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

    Get PDF
    AIMS: In coronavirus disease 2019 (COVID-19), myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in patients with COVID-19, myocardial injury, and heightened inflammation. METHODS AND RESULTS: This trial required hospitalization due to COVID-19, elevated troponin, and a C-reactive protein concentration more than 50 mg/L. The primary endpoint was time to clinical improvement at Day 14, defined as either an improvement of two points on a seven-category ordinal scale or discharge from the hospital. The secondary endpoint was mortality at Day 28. Forty-five patients were randomly assigned to canakinumab 600 mg ( CONCLUSION: There was no difference in time to clinical improvement at Day 14 in patients treated with canakinumab, and no safety concerns were identified. Future studies could focus on high dose canakinumab in the treatment arm and assess efficacy outcomes at Day 28

    Status of the ACCULINNA-2 project at FLNR

    Get PDF
    The project of a new and more powerful in-flight fragment separator ACCULINNA-2 at U-400M cyclotron in FLNR, JINR planned to build in addition to the existing separator ACCULINNA is presented. The new separator will provide high intensity RIBs in the lowest energy range (5÷50 MeV/nucleon) which is attainable for in-flight separators. The possibilities for the astrophysics studies at the proposed device are presented. ACCULINNA-2 separator is planned to be constructed in the years 2010-2015. The current status of the project is reported

    The SysteMHC Atlas project.

    Get PDF
    Mass spectrometry (MS)-based immunopeptidomics investigates the repertoire of peptides presented at the cell surface by major histocompatibility complex (MHC) molecules. The broad clinical relevance of MHC-associated peptides, e.g. in precision medicine, provides a strong rationale for the large-scale generation of immunopeptidomic datasets and recent developments in MS-based peptide analysis technologies now support the generation of the required data. Importantly, the availability of diverse immunopeptidomic datasets has resulted in an increasing need to standardize, store and exchange this type of data to enable better collaborations among researchers, to advance the field more efficiently and to establish quality measures required for the meaningful comparison of datasets. Here we present the SysteMHC Atlas (https://systemhcatlas.org), a public database that aims at collecting, organizing, sharing, visualizing and exploring immunopeptidomic data generated by MS. The Atlas includes raw mass spectrometer output files collected from several laboratories around the globe, a catalog of context-specific datasets of MHC class I and class II peptides, standardized MHC allele-specific peptide spectral libraries consisting of consensus spectra calculated from repeat measurements of the same peptide sequence, and links to other proteomics and immunology databases. The SysteMHC Atlas project was created and will be further expanded using a uniform and open computational pipeline that controls the quality of peptide identifications and peptide annotations. Thus, the SysteMHC Atlas disseminates quality controlled immunopeptidomic information to the public domain and serves as a community resource toward the generation of a high-quality comprehensive map of the human immunopeptidome and the support of consistent measurement of immunopeptidomic sample cohorts

    Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection.

    Get PDF
    Distinct molecular pathways govern the differentiation of CD8+ effector T cells into memory or exhausted T cells during acute and chronic viral infection, but these are not well studied in humans. Here, we employed an integrative systems immunology approach to identify transcriptional commonalities and differences between virus-specific CD8+ T cells from patients with persistent and spontaneously resolving hepatitis C virus (HCV) infection during the acute phase. We observed dysregulation of metabolic processes during early persistent infection that was linked to changes in expression of genes related to nucleosomal regulation of transcription, T cell differentiation, and the inflammatory response and correlated with subject age, sex, and the presence of HCV-specific CD4+ T cell populations. These early changes in HCV-specific CD8+ T cell transcription preceded the overt establishment of T cell exhaustion, making this signature a prime target in the search for the regulatory origins of T cell dysfunction in chronic viral infection

    Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

    Get PDF
    BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)
    corecore